Orexo issues bonds of SEK 325 million and confirms fulfilment of condition under notice of early redemption

Uppsala, Sweden – October 31, 2017 – Orexo AB (publ.) (the “Company”) has issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, due in November 2021. The bond loan has a floating interest rate of STIBOR 3m +4.50 per cent per year (quarterly payments in arrears). The net proceeds from the issue will mainly be used towards prepayment of the Company’s existing outstanding bond loan and for general corporate purposes. The issue date for the new bonds is expected to be 13 November 2017.

The Company intends to list the new bonds on the corporate bond list of Nasdaq Stockholm.

The Company hereby also announces that the condition set out in the Company’s notice of early total redemption of the existing bond loan (ISIN SE0005932159) has been fulfilled. Accordingly, the redemption of the existing bond loan will be completed as planned, on 22 November 2017. The record date will be 15 November 2017. For further information, please refer to Orexo’s press release on 27 October 2017.

“We are very pleased with the continued interest among investors for an Orexo bond. The bond issue leaves us in a strong financial position and enables us to continue our strategy and take advantage of market opportunities when they occur,” comments Nikolaj Sørensen, CEO and president of Orexo AB.

Pareto Securities has acted as sole bookrunner in the transaction and Gernandt & Danielsson Advokatbyrå has acted as legal adviser to Pareto Securities. Advokatfirman Vinge has acted as legal adviser to Orexo.

For further information, please contact:

About Orexo

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com. 

Tags: